Alzheimer's Disease
Stay at the forefront of Alzheimer's disease research and care with insights from the Lancet, featuring groundbreaking research and authoritative reviews that inform the latest advances in diagnosis, treatment, and patient care.
Research in Context
Research in Context is a structured summary that editors at The Lancet’s journals ask all authors to provide when submitting an original research article. Read more
Featured Article
Genetic loci linked to onset-age variability in autosomal dominant Alzheimer's disease
A genome-wide association study identified three loci associated with onset-age variability across ADAD genes.
The Lancet Group reaches millions of clinicians and researchers worldwide.
Sequential plasma biomarker strategy evaluated for Alzheimer's disease
In a memory clinic cohort, researchers tested whether plasma %p-tau217 followed by eMTBR-tau243 could help distinguish asymptomatic amyloid pathology from established Alzheimer's disease.
Discontinuing cholinesterase inhibitors in Alzheimer's disease: evidence from France's reimbursement withdrawal
A quasi-experiment and target trial emulation study reported that discontinuation was linked with faster cognitive decline, without survival benefit, in a real-world French Alzheimer's disease population.
First NIH-supported Alzheimer's prevention trial in PSEN1 carriers reported
A Research in Context piece on the API ADAD Colombia Trial notes that robust fibrillar amyloid removal appears necessary for clinical efficacy in people with elevated brain amyloid, and outlines a new data-sharing precedent for future trials.
Frailty and prognosis in Alzheimer's disease
In this Swedish register-based cohort study, frailty was associated with institutionalisation and survival outcomes, but not with cognitive decline rate.
APOE disclosure in cognitively unimpaired adults: psychological impact in a trial pre-screening cohort
A study in The Lancet Healthy Longevity suggests APOE genotype disclosure was well tolerated in a trial pre-screening cohort of cognitively unimpaired adults who were psychologically ready, willing, and received results from an experienced health-care provider.
Neuropathological findings after aducanumab treatment in Alzheimer's disease
A case–control postmortem analysis of aducanumab-treated vs. therapy-naive participants suggests spatially restricted Aβ clearance and describes ARIA-associated vascular changes.
Lab-based γ-secretase activity measures linked to Alzheimer's disease progression, researchers stress validation still needed.
Findings from cell-based assays, not yet clinically validated, suggest PSEN1 variant-level differences in γ-secretase activity could help explain disease heterogeneity, pending confirmation in prospective longitudinal studies.
Oral semaglutide 14 mg did not slow clinical decline in early-stage Alzheimer's disease trials
The evoke and evoke+ phase 3 trials found no superiority of oral semaglutide 14 mg versus placebo on cognitive or global decline in biomarker-confirmed early Alzheimer's disease, with reductions in CSF biomarkers reported in a separate substudy.